Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Updated: Mylan Presses On With US Tecfidera Launch ‘At Risk’

Follows First FDA Approval For Rival To MS Blockbuster

Executive Summary

Facing an appeal on a favorable US district court decision, Mylan has opted to launch “at risk” the first generic Tecfidera in the US, after obtaining FDA approval and seeing the originator’s bid for injunctive relief shot down earlier this month.

You may also be interested in...



Federal Circuit Cements Viatris Victory Over Biogen On Key US Tecfidera Patent

As anticipated by the street, Viatris has prevailed over Biogen on the originator’s appeal of a district court ruling that invalidated a key US patent shielding its Tecfidera treatment for multiple sclerosis. However, the Federal Circuit was not aligned on its decision.

Sandoz Canada Debuts Tecfidera Rival

Sandoz has announced its launch of a generic rival to Tecfidera in Canada, with the firm among the first generics to be issued a notice of compliance by Health Canada.

FDA’s OGD Takes Fight To COVID-19 With Half-Century Of Approvals

The sixth annual report of the FDA’s Office of Generic Drugs covered a year dominated by the novel coronavirus pandemic – although first-time generic approvals and record levels of communication also featured prominently.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150180

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel